146 related articles for article (PubMed ID: 32041835)
1. Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.
Hähnel T; Baldow C; Guilhot J; Guilhot F; Saussele S; Mustjoki S; Jilg S; Jost PJ; Dulucq S; Mahon FX; Roeder I; Fassoni AC; Glauche I
Cancer Res; 2020 Jun; 80(11):2394-2406. PubMed ID: 32041835
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
[TBL] [Abstract][Full Text] [Related]
3. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
4. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
Elsayed AG; Srivastava R; Jamil MO
Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389
[TBL] [Abstract][Full Text] [Related]
5. Treatment-free remission and immunity in chronic myeloid leukemia.
Ureshino H
Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Ross DM; Pagani IS; Shanmuganathan N; Kok CH; Seymour JF; Mills AK; Filshie RJ; Arthur CK; Dang P; Saunders VA; Braley J; Yong AS; Yeung DT; White DL; Grigg AP; Schwarer AP; Branford S; Hughes TP;
Leukemia; 2018 Dec; 32(12):2572-2579. PubMed ID: 30315232
[TBL] [Abstract][Full Text] [Related]
7. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
8. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data.
Fassoni AC; Baldow C; Roeder I; Glauche I
Haematologica; 2018 Nov; 103(11):1825-1834. PubMed ID: 29954936
[TBL] [Abstract][Full Text] [Related]
9. Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia.
Kim E; Hwang EJ; Lee J; Kim DY; Kim JY; Kim DW
Neoplasia; 2022 Oct; 32():100817. PubMed ID: 35878453
[TBL] [Abstract][Full Text] [Related]
10. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
Mahon FX; Etienne G
Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
Spiess B; Rinaldetti S; Naumann N; Galuschek N; Kossak-Roth U; Wuchter P; Tarnopolscaia I; Rose D; Voskanyan A; Fabarius A; Hofmann WK; Saußele S; Seifarth W
PLoS One; 2019; 14(3):e0214305. PubMed ID: 30897165
[TBL] [Abstract][Full Text] [Related]
12. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
13. Treatment-Free Remission: the New Goal in CML Therapy.
Atallah E; Sweet K
Curr Hematol Malig Rep; 2021 Oct; 16(5):433-439. PubMed ID: 34618317
[TBL] [Abstract][Full Text] [Related]
14. When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Laneuville P
Curr Treat Options Oncol; 2018 Mar; 19(3):15. PubMed ID: 29520446
[TBL] [Abstract][Full Text] [Related]
15. Treatment-Free Remission in CML: the US Perspective.
Guru Murthy GS; Atallah E
Curr Hematol Malig Rep; 2019 Feb; 14(1):56-61. PubMed ID: 30645715
[TBL] [Abstract][Full Text] [Related]
16. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
Baccarani M; Abruzzese E; Accurso V; Albano F; Annunziata M; Barulli S; Beltrami G; Bergamaschi M; Binotto G; Bocchia M; Caocci G; Capodanno I; Cavazzini F; Cedrone M; Cerrano M; Crugnola M; D'Adda M; Elena C; Fava C; Fazi P; Fozza C; Galimberti S; Giai V; Gozzini A; Gugliotta G; Iurlo A; La Barba G; Levato L; Lucchesi A; Luciano L; Lunghi F; Lunghi M; Malagola M; Marasca R; Martino B; Melpignano A; Miggiano MC; Montefusco E; Musolino C; Palmieri F; Pregno P; Rapezzi D; Rege-Cambrin G; Rupoli S; Salvucci M; Sancetta R; Sica S; Spadano R; Stagno F; Tiribelli M; Tomassetti S; Trabacchi E; Bonifacio M; Breccia M; Castagnetti F; Pane F; Russo D; Saglio G; Soverini S; Vigneri P; Rosti G
Blood Adv; 2019 Dec; 3(24):4280-4290. PubMed ID: 31869412
[TBL] [Abstract][Full Text] [Related]
17. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
McCarron SL; O'Connor LM; Langabeer SE; Conneally E
Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
[TBL] [Abstract][Full Text] [Related]
19. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
Antoszewska-Smith J; Pawlowska E; Blasiak J
Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
[TBL] [Abstract][Full Text] [Related]
20. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani YD; Kok CH; Clarson J; Shanmuganathan N; Branford S; Yeung DT; Ross DM; Hughes TP; Yong ASM
Blood Adv; 2023 Jun; 7(11):2364-2374. PubMed ID: 36622326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]